Articles By Rob Wright, Chief Editor
35-Year Biopharma R&D Vet Takes On His Second Startup9/1/2021
Norbert Bischofberger, Ph.D., had a good job at Gilead where he had worked for nearly two decades. Then, out of the blue, he found out he was being considered for a CEO position at a small startup called Kronos Bio.
Can Employers Deliver On What Today’s Employees Seek?9/1/2021
The big question on the minds of all companies is: Is it possible to achieve what today’s employees seek in a 100% virtual environment?
What’s It Like Being A First-Time Biopharma CEO?9/1/2021
In this edited transcript of our June 2021 executive virtual roundtable, three first-time CEOs tell us their tales of the good, the bad, and the ugly related to being CEO.
When It’s Time8/2/2021
When pondering if she wanted to spend the next 10 to 15 years continuing to climb that academic ladder or do something that would be impactful for patients, Laura Niklason, M.D., Ph.D., opted for the latter.
From Professor To Regenerative Medicine Company CEO8/2/2021
Though she cofounded the company in 2004 and played an active role throughout its growth, until November 2020, Laura Niklason, M.D., Ph.D., had never held a c-level title within it.
IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public8/2/2021
Taking a company public may not be every entrepreneur’s dream, but it is for many life sciences companies. As 2020 forever changed how IPOs are done, it seems like there is a great opportunity to capture some wisdom from those who have been there, done that.
Mental Wellness — The Next Big Thing7/30/2021
Recent events of female athletes expressing the need to focus on their mental health seems to point toward mental wellness being one of the next big things, along with women leaders being willing to "rewrite the rules."
Is Government-Enabled IP Theft Ever A Good Thing?7/1/2021
I believe waiving IP protections on COVID-19 vaccines (developed by three U.S. companies in record time) will not have any appreciable impact on fixing the global health crisis in the short term.
How A First-Time CEO Transformed Retrophin Into Travere Therapeutics7/1/2021
Eric Dube, Ph.D., was dubious when an executive recruiter pitched him the CEO position at previously embattled Retrophin (remember Martin Shkreli?). But he took the job in January 2019 and now has guided the $1.5 billion biopharma as it has increased sales, implemented a new diverse and inclusive culture, advanced its pipeline, and adopted a new name (Travere).